Glioblastoma – Berubicin for the Treatment of Recurrent Disease
Overview Based on its potential to prolong overall survival in patients with Glioblastoma, GBM, Berubicin was granted Fast Track Designation by the American Food and
Cervical Cancer – Accelerated Approval to Tivdak
About the FDA decision in Cervical Cancer The Food and Drug Administration, the FDA, has granted an accelerated approval to Tivdak (Tisotumab Vedotin-tftv) for the
Nasopharyngeal Carcinoma – Toripalimab, A New Breakthrough Drug
Overview Nasopharyngeal carcinoma is a malignant tumor that affects the head and neck. Typically, this cancer starts in the upper part of the throat and
“Significant improvement. Now no evidence of active malignancy”
He is our client, a charming 58 year old man and has colorectal cancer with liver metastases. He received the standard protocol until he reached
Melanoma – UV1 plus Keytruda, A Breakthrough
Overview Melanoma is a unique type of skin cancer that originates from cells known as melanocytes. The main function of these cells is to produce
Triple Negative Breast Cancer – Leronlimab Plus Chemo Appears to Prolong Survival
Straight to the Point in Triple Negative Breast Cancer Leronlimab (PRO 140) has demonstrated promising preliminary results in a phase 1b/2 clinical trial (NCT03838367) for
Triple Negative Breast Cancer and a New Drug, Trilaciclib
Overview Doctors often struggle with treating advanced stages of breast cancer, especially Triple Negative Breast Cancer, TNBC. When the tumor is located in a confined
The standard protocol – do the same and get the same. Upsetting!
The treatment that is given “according to the book” to everyone, is called in professional language “the standard protocol”. LB, our client, 62, was diagnosed
Prostate Cancer Breakthrough Drug Combination for Metastatic Patients
Background Despite the advances and strides that modern medicine has made, prostate cancer treatment options remain to be fairly reserved. However, the day is finally
Breast Cancer – The Potential Use of SYD985
Overview – Breast cancer and [vic-]trastuzumab duocarmazine (SYD985) and In a recent press release by Byondis, the pharmaceutical company expressed excitement and optimism about the
Fecal Microbiota Transplant in melanoma patients
Background The utilization of FMT can influence how metastatic melanoma patients respond to anti-PD-1 immunotherapy. Numerous microbes inhabit the human gut. The colon itself has
